Novartis adds to portfolio with acquisition of IFM Tre
BASEL –Novartis announced Monday that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome.